Pediatric Study Planning Should Occur Early In Drug Development, FDA Says
Executive Summary
Sponsors of drugs for serious or life-threatening diseases should discuss pediatric study plans with FDA at pre-IND and end-of-Phase I meetings, the agency recommends in a draft guidance